COVID rebound following Pfizer treatment is likely due to a strong immune system, study shows
The rebound in the symptoms of COVID-19 in certain patients after taking Pfizer (NYSE:PFE)’s Antiviral Paxlovid could be related to a strong immune system rather as a weaker one U.S. government researchers reported on Thursday.
They concluded that an extended course of medication – over the recommended 5 days did not have to be done to lower the chance of flare-up of symptoms as some have suggested. after a thorough investigation of rebound among eight patients from the Institute of Medicine’s Clinical Center.
Related: Oil prices go down because China is putting limits on COVID and because interest rates might go up.
The majority of patients were immune-compliant however, the researchers observed greater levels of antibodies among those who had the rebound.
The researchers said that their research support the idea that compromised immune responses are the reason that symptoms are recurring in certain patients.
“Our results suggest that more powerful immune response, rather than an uncontrolled viral replication accounts for these clinical rebounds” the researchers reported.
The study, which was published within the Journal of Clinical Infectious Diseases, followed several reports of people who had taken Paxlovid according to the recommended dosage within five days of acquiring the infection. The patients noticed a recurrence of symptoms once they had completed the course of treatment lasting five days.
Vice President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced COVID-related rebound after taking the drug.
The case raised the possibility that Pfizer’s two-drug antiviral regimen could hinder the creation of a lasting immune response.
The study included six participants who’s COVID symptoms returned following the use of Paxlovid in addition to two patients who had the symptoms of rebound after apparent recovery, but who didn’t take the medication. The results were compared with the group of six who suffered from COVID, but didn’t experience an increase in symptoms. All participants were vaccinated and boosters and all had one form of the Omicron version that causes the disease.
Study participants’ blood samples were subjected to intense examination to evaluate their immune responses in the acute infection phase as well as the rebound stage.
All rebound patients have seen significant improvements in their symptoms prior their rebound. In the case of those who experienced rebounded after Paxlovid 4 had less symptoms than they did during their initial infection. One suffered similar severity, and one had more severe symptoms.
None of the patients who recurred required hospitalization or additional treatment.
Related: COVID saps China’s consumer and producer inflation in August.
Rebound symptoms could be due to a robust immune response to viruses that remain that is present in respiratory systems, researchers suggest. Researchers concluded that this medication is not hindering the immune system in certain people, as some been imagining.
More extensive and thorough studies are required to better comprehend COVID symptoms that rebound The research team stated and added that the present evidence supports the need for the isolation of these patients.
The researchers also stated that there’s the need to study the longer duration of Paxlovid in patients with immunocompromised conditions where the immune system may not be effective.
